FDA Video Series Highlights Promise of Biosimilars

The FDA recently released a new 5-part video series highlighting biosimilars and interchangeable products. As part of a larger education and outreach effort, the video series provides an overview of the products and focuses on key concepts about development and approval. To date, the FDA has approved 10 biosimilars.

In the first video of the series, which is posted to the FDA's youtube page, FDA Commissioner Scott Gottlieb, MD, and Leah Christl, PhD, Director of OND Therapeutics Biologics and Biosimilars Staff, CDER, FDA, discuss the promise that biosimilars offer in terms of providing more treatment options, more access to medications that can save lives, and the possibility that market competition can drive down the cost of health care. 

"More and more drugs we see coming onto the market are biological products, and so a lot of the important treatments for cancers, a lot of important treatment for rare diseases or different disorders, are biological products," Dr Gottlieb said in the video. 

The video highlights the FDA's abbreviated pathway to approval for biosimilar products and how it can reduce development costs and time to market, which can continue to open more doors for biosimilars. 

"They're just as safe and effective as their traditional counterparts, and they could provide enormous savings to consumers through product competition," Dr Gottlieb concluded in the video. 

For more information, watch the first video of the series below.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Perspective on the factors that determine inclusion of biosimilars onto a formulary.
Considerations for educating patients and providers on the role that biosimilars have in the treatment plan and their associated costs.
Considerations on the role of specialty pharmacies with regard to the dispensing of biosimilars versus biologics.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.